3 years ago

Pericarditis during infliximab therapy in paediatric ulcerative colitis

Pericarditis during infliximab therapy in paediatric ulcerative colitis
V. Dipasquale, M. A. Catena, C. Romano, S. M. C. Gramaglia
What is known and study objective Infliximab is a widely used drug for treating inflammatory bowel disease (IBD). This drug is known to rarely cause pericarditis in adult populations. Case summary This report details the case of a 14-year-old boy with ulcerative colitis who developed pericarditis after a second infliximab infusion. After discontinuation of therapy, the patient's symptoms were resolved. What is new and conclusion To our knowledge, this is the first reported paediatric case of pericarditis as a possible complication of infliximab therapy in IBD. Among infliximab-related delayed adverse reactions, cardiac complications should be monitored in the paediatric population. Infliximab, a widely used drug for treating inflammatory bowel disease (IBD), is known to rarely cause pericarditis in adult populations. In this report, we communicate a case of pericarditis after a second infliximab infusion in a 14-year-old boy with ulcerative colitis. To our knowledge, this is the first reported paediatric case of pericarditis as a possible complication of infliximab therapy in IBD.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/jcpt.12586

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.